Standout Papers

HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/G... 2017 2026 2020 2023 355
  1. HALO 202: Randomized Phase II Study of PEGPH20 Plus Nab-Paclitaxel/Gemcitabine Versus Nab-Paclitaxel/Gemcitabine in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma (2017)
    Sunil R. Hingorani, Lei Zheng et al. Journal of Clinical Oncology

Immediate Impact

9 by Nobel laureates 32 from Science/Nature 76 standout
Sub-graph 1 of 18

Citing Papers

Pancreatic cancer
2025 Standout
Palliative Care for Patients With Cancer: ASCO Guideline Update
2024 Standout
19 intermediate papers

Works of Nathan Bahary being referenced

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers
2019
A Pilot Trial of Early Specialty Palliative Care for Patients with Advanced Pancreatic Cancer: Challenges Encountered and Lessons Learned
2017
and 18 more

Author Peers

Author Last Decade Papers Cites
Nathan Bahary 3190 1139 1088 1793 1428 185 6.2k
Satoshi Fujii 2376 1225 1357 2301 1344 265 6.6k
Patrick Michl 2767 788 536 2308 1241 153 5.7k
Marcella Mottolese 3041 524 908 3517 1515 224 7.1k
Muh‐Hwa Yang 2835 832 949 3915 2118 161 7.4k
Claudio Ceccarelli 2625 1569 1030 3168 1442 204 8.6k
Anthony Montag 2523 1865 1766 2975 1217 144 9.0k
R. Yoshiyuki Osamura 1842 1179 843 1805 738 325 6.5k
Ying‐Hong Shi 1736 918 716 3028 1884 187 6.5k
Shinji Tanaka 2233 1360 1090 3864 1796 253 7.2k
Ronald A. DeLellis 2255 1755 944 2388 1165 201 8.3k

All Works

Loading papers...

Rankless by CCL
2026